RxDoctor Payments Data

Pranaychandra Vaidya

Interventional Cardiology · Hackensack, NJNPI 1659322204

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $30,869 of the $49,811 with a category attached, or 62.0%. Amgen accounts for 65.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $16,945 and has fallen 64.5% since, to $6,015 in 2025.

$49,811in general payments, 2019–2025

Across 252 payments — averaging $197.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$33K
  • Medtronic$8K
  • Abiomed$6K
  • Abbott$640
  • Boston Scientific$583
  • Edwards Lifesciences$471
  • plus $2K from 15 others
$6,439in research payments, 2019–2025

Across 28 payments — averaging $229.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$6K
  • Abiomed$119

What the payments were for

  • Speaking & faculty fees$30,86962%
  • Travel & lodging$6,89214%
  • Food & beverage$11,91424%
  • Education$1360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$49,811 in reported general payments places this provider in the 85th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$110,682
Medicare patients
839
Services billed
1,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$94,815
EntrestoSacubitril/Valsartan23$27,540
Repatha SureclickEvolocumab11$8,910
VytorinEzetimibe/Simvastatin11$4,230
Ranolazine ErRanolazine27$3,286
Metoprolol Succinate153$3,013
Atorvastatin Calcium137$1,459
ClopidogrelClopidogrel Bisulfate100$1,292
Rosuvastatin Calcium72$849
Amlodipine Besylate84$748
Ezetimibe41$684
Furosemide81$487
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$452
Losartan Potassium26$407
Carvedilol13$277

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →